Prostate Cancer Archive

Every year, millions of men around the world get a prostate-specific antigen (PSA) test. Abnormal readings on the test suggest a man might have prostate cancer. But how should an abnormal result be interpreted?

High-resolution micro-ultrasound may be an efficient alternative to using MRI plus conventional ultrasound to guide prostate biopsies, according to a 2025 study. The micro-ultrasound method proved as accurate as MRI guidance, but requires fewer visits and costs less.

For men who choose prostate cancer screening, it begins with measuring prostate-specific antigen (PSA) in the blood. Scientists continue to explore strategies beyond PSA testing to identify men who should have biopsies because they are more likely to have intermediate or high-risk cancer. These strategies include other types of PSA measurements, urine tests for genes, new imaging methods and artificial intelligence that works to improve the accuracy and efficiency of MRI and biopsies.

The US Preventive Services Task Force recommends against screening for prostate cancer in men older than 70, but as life expectancy for this group increases and treatment options evolve, it's important for men to be aware of their options.

Most men with prostate cancer have low-grade cancer, meaning the cancer is unlikely to spread or affect quality of life or longevity. But men whose initial prostate biopsy shows an intermediate-risk or high-risk cancer, or those who began active surveillance for low-risk cancer but develop a rising PSA or new symptoms suggesting aggressive cancer, have several treatment options available. These include different combinations of radiation, surgery, androgen deprivation therapy, chemotherapy, immunotherapy, and anti-androgens.

Looking after a loved one who has prostate cancer can be overwhelming. Caregivers play crucial roles in supporting a patient's physical and psychological well-being. But what does that entail? Here's what to know about effective communication, day-to-day support, and taking care of yourself.

Roughly one in six men will be diagnosed with prostate cancer at some point in their lives, but these cancers usually aren't life-threatening. The least risky form of the disease occurs frequently with age, will not metastasize to other parts of the body, and it doesn't require any immediate treatment. So, should it even be called cancer?

Researchers are developing tools for predicting how fast prostate cancer might progress; among the most promising are those that count circulating tumor cells (CTCs) in blood samples. Research shows that high CTC counts predict poorer survival and faster disease progression. But they are also predictive for early-stage metastatic prostate cancer that still responds to hormonal therapy.

In a 2024 study, transperineal prostate biopsies were less likely to cause infections than traditional transrectal biopsies. Transperineal biopsies retrieve tissue samples using a thin needle inserted through the skin between the scrotum and rectum.